Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alfatex
- Development stage
- Unknown
- Lead developer
- SIFI
- Modality
- Peptides, Small Molecules
- Administration
- Ophthalmic
01
Overview
Alfatex is an approved ophthalmic fixed-dose combination drug developed by Alfa Intes. It is formulated as eye drops (powder and solvent for solution) and an eye ointment, combining the synthetic corticosteroid betamethasone with three antibiotics: chloramphenicol, colistimethate sodium, and tetracycline (or rolitetracycline). This combination provides both potent anti-inflammatory and broad-spectrum antibacterial activities. Alfatex is indicated for the treatment of various inflammatory and infectious ocular conditions, including allergic, vernal, phlyctenular, and infectious conjunctivitis, blepharitis, blepharoconjunctivitis, keratitis, keratoendotheliitis, scleritis, episcleritis, uveitis, and post-surgical or post-traumatic ocular inflammation.
- Brand names
- Alfatex
- Other names
- betamethasone + chloramphenicol + colistimethate + rolitetracyclinebetamethasone + chloramphenicol + colistimethate + tetracyclinebetamethasone + chloramphenicol + colistimethate sodium + rolitetracyclinebetamethasone + chloramphenicol + colistimethate sodium + tetracyclinebetametasone + cloramfenicolo + colistimetato + rolitetraciclinabetametasone + cloramfenicolo + colistimetato + tetraciclinabetametasone + cloramfenicolo + colistimetato di sodio + tetraciclinabetametasone + cloramfenicolo + colistimetato sodico + rolitetraciclina
02
Targets
Bacterial 50S ribosomal subunitMitoribosome (Mitochondrial ribosome)GR (Glucocorticoid receptor)Bacterial Ribosome
Beyond the preview
Go deeper on Alfatex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alfatex.